Evidence map›Paper›PMID 33368820›Full record

ArticlePharmacoepidemiology and drug safety2021

Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials.

Gema Requena, Achim Wolf, Rachael Williams, Daniel Dedman, Jennifer K Quint, Tarita Murray-Thomas, Jeanne M Pimenta

Open access · hybridAbstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Gema RequenaRespiratory Epidemiology, GlaxoSmithKline, Brentford, UK.ORCID 0000-0002-1889-6656
Achim WolfClinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.
Rachael WilliamsClinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.ORCID 0000-0001-9007-6292
Daniel DedmanClinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.
Jennifer K QuintRespiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, London, UK.
Tarita Murray-ThomasClinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.
Jeanne M PimentaRespiratory Epidemiology, GlaxoSmithKline, Brentford, UK.
Clinical Practice Research Datalink · GBGlaxoSmithKline (United Kingdom) · GBLung Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial.

methodsA retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow-up time and types of losses during follow-up. Characteristics were evaluated using descriptive statistics.

resultsA total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3-5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow-up at 1, 2, and 5 years (92%, 85% and 67%, respectively).

conclusionsPatients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.

Indexed as

Data ManagementPulmonary Disease, Chronic ObstructiveAgedCohort StudiesDatabases, FactualFeasibility StudiesFemaleHumansMaleRetrospective StudiesUnited Kingdomchronic obstructive pulmonary diseaseelectronic health recordfeasibility studiesgeneral practiceprimary health carereal world clinical trials

Identifiers

PMID33368820
PMCPMC7986187
OpenAlexW3114034175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.